SCHEMBL953404

SCHEMBL953404

NC(=O)c1sc(-c2ccnc3[nH]ccc23)nc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.55
DBF4 Q9UBU7 3/20 0.55
CCNE1 P24864 1/20 0.55
CDK2 P24941 1/20 0.55
PRKCI P41743 2/20 0.55
NUDT1 P36639 3/20 0.54
IKBKB O14920 3/20 0.53
CHUK O15111 3/20 0.53
ROCK1 Q13464 2/20 0.53
AURKB Q96GD4 2/20 0.53
JAK2 O60674 2/20 0.53
DAPK3 O43293 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
PAK4 O96013 1/20 0.53
CSF1R P07333 1/20 0.53
RET P07949 1/20 0.53
IGF1R P08069 1/20 0.53
FGFR1 P11362 1/20 0.53
PRKACA P17612 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL955682 0.91 AURKB (0.56) CDC7DBF4PRKCINUDT1IKBKB
SCHEMBL4740819 0.75 CDC7 (0.85) CDC7DBF4CCNE1CDK2
SCHEMBL953158 0.74 CDC7 (0.56) CDC7DBF4CCNE1CDK2KDR
SCHEMBL956033 0.74 JAK2 (0.51) PRKCINUDT1IKBKBCHUKROCK1
SCHEMBL857275 0.72 IKBKB (1.00) PRKCINUDT1IKBKBCHUKROCK1
SCHEMBL15064348 0.72 CDC7 (0.62) CDC7DBF4CCNE1CDK2
SCHEMBL4764911 0.71 NUDT1 (0.71) PRKCINUDT1IKBKBCHUKROCK1
SCHEMBL10125558 0.71 PRKCI (1.00) CDC7CDK2PRKCINUDT1IKBKB
SCHEMBL4583792 0.71 NUDT1 (0.60) CDK2PRKCINUDT1IKBKBCHUK
SCHEMBL954078 0.71 CDC7 (0.68) CDC7DBF4CCNE1CDK2CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
CN-102395585-A Heteroaryls and their use as pi3k inhibitors MILLENNIUM PHARM INC 2012-03-28 CN disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885CCNE1 1329/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885CCNE1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.